Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 4/20 | 0.66 |
| ▸ | SHMT1 | P34896 | 5/20 | 0.60 |
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255500 | 0.89 | SHMT1 (0.73) | SHMT2SHMT1KDM4ELMNAHTT | |
| SCHEMBL21560156 | 0.89 | SHMT1 (0.73) | SHMT2SHMT1KDM4ELMNAHTT | |
| SCHEMBL20255722 | 0.88 | LMNA (0.67) | SHMT2SHMT1FPR2KDM4ELMNA | |
| SCHEMBL21560205 | 0.88 | LMNA (0.67) | SHMT2SHMT1FPR2KDM4ELMNA | |
| SCHEMBL20255653 | 0.87 | SHMT1 (0.63) | SHMT2SHMT1FPR2KDM4ELMNA | |
| SCHEMBL20256002 | 0.87 | SHMT1 (0.66) | SHMT2SHMT1KDM4ELMNAHTT | |
| SCHEMBL20255997 | 0.87 | SHMT1 (0.66) | SHMT2SHMT1KDM4ELMNAHTT | |
| SCHEMBL21560291 | 0.86 | SHMT2 (0.66) | SHMT2SHMT1KDM4ELMNAHTT | |
| SCHEMBL20255462 | 0.85 | SHMT2 (0.55) | SHMT2SHMT1LMNAHTT | |
| SCHEMBL20255808 | 0.85 | SHMT2 (0.55) | SHMT2SHMT1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | SHMT2 2/4885SHMT1 1/4885FPR2 4195/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | SHMT2 2/4885SHMT1 1/4885FPR2 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.